In addition, it addresses the FDA’s communications With all the applicant, the retention of documents that aid the SE report, confidentiality of an SE report, how an applicant can amend or withdraw an SE report, how an applicant may possibly transfer ownership of the SE report back to a different applicant and electronic submission in the SE repo